A physician listens to an older patient’s chest with a stethoscope. A physician listens to an older patient’s chest with a stethoscope.

Veracyte’s approach to interstitial lung disease (ILD) testing

About ILD diagnosis and treatment

Interstitial lung disease (ILD) refers to a large group of disorders that cause scarring of the lung. Idiopathic pulmonary fibrosis (IPF) is one of the most common and deadly forms of ILD. It is marked by progressive disease that eventually prevents oxygen from reaching the blood stream. Early and accurate diagnosis of IPF and other progressive forms of ILD is important so that patients can receive appropriate and timely treatment and avoid potentially harmful procedures.

ILD diagnosis is often made by a multi-disciplinary team of pulmonologists, radiologists and pathologists. Identifying usual interstitial pneumonia (UIP) is essential to IPF diagnosis. UIP is also associated with other progressive forms of ILD. Physicians routinely use high-resolution computed tomography (HRCT) to identify UIP. However, clear identification of UIP using just HRCT and clinical factors is often challenging. This uncertainty can lead to unnecessary invasive procedures, as well as delayed or inappropriate treatment. In a survey of patients diagnosed with ILD, 43% reported taking a year or longer to obtain an accurate diagnosis and more than half (55%) reported being misdiagnosed at least once.1

Veracyte is applying the power of genomic and machine-learning technology to give physicians more clarity and confidence in ILD diagnosis and prognosis.


patients are evaluated for ILD in the US, Europe and APAC annually.2


of those patients lack a highly confident diagnosis.3


Learn about our exceptional ILD diagnostics.

Identifying unmet needs through listening and collaboration

At Veracyte, we listen and collaborate with physicians to understand where our advanced technology can truly make a difference in patient care. Our work with leading experts who diagnose and treat ILD revealed the importance of helping them better identify patients with UIP, without the need for surgery. This could help them better distinguish IPF from other ILDs and is important for guiding initial treatment, which typically includes antifibrotic therapy. Through our collaboration with experts, we saw an opportunity for new testing to provide clarity into this key aspect of the diagnostic process.

We also continue to work with physicians to identify additional opportunities for our testing to help improve care for patients with ILD.

Conventional approaches to diagnosing IPF and other progressive forms of ILD are limited, often leaving physicians and their patients unsure about next steps. We believe genomic testing provides clearer information that enables physicians to make more confident ILD diagnoses and in turn ensure better patient care.”

Medical Director for Pulmonology, Veracyte

A physician attends to an older patient lying in a hospital bed.


More confident diagnosis and prognosis with Envisia® Genomic Classifier

Veracyte’s Envisia Genomic Classifier is the first commercially available genomic test to help improve physicians’ ability to differentiate IPF from other ILDs. This can enable timely and appropriate treatment. The test combines powerful RNA sequencing and machine-learning technology to identify a genomic pattern of UIP in tissue from the lungs. UIP is critical to the diagnosis of IPF and is associated with a poor prognosis across multiple types of ILD.

An older couple embrace and laugh together at dinner.

Learn about Envisia Genomic Classifier for ILD


  1. Cosgrove GP, et al. BMC Pulm Med. 2018.

  2. Company estimates.

  3. Company estimates based on proportion of patients classified by various CT scan patterns (from Chung JH, et al. CHEST. 2015.).

The Envisia Genomic Classifier is available in the US as part of Veracyte’s CLIA-validated laboratory developed test (LDT) service. This test has not been cleared or approved by the FDA.

This website contains information on products that are targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for you accessing such information that may not comply with any legal process, regulation, registration or usage in the country of your origin.